Nomination Period For The Broermann Medical Innovation Award Started

January 17, 2025 10:35 PM AEDT | By Pressat
 Nomination Period For The Broermann Medical Innovation Award Started
Image source: Kalkine Media
Friday 17 January, 2025

Gießen -

Prize money of one million euros higher than the prize money for the
Nobel Prize for Medicine


Award honors researchers worldwide who have done pioneering work in
medicine, biotechnology, or related fields



The nomination period for the Broermann Medical Innovation Award has
started. The prize, which will be awarded for the first time this year,
is aimed at scientists worldwide who have carried out pioneering work in
medicine, biotechnology, or related fields with their research.


The nomination portal (www.broermann-award.org/nomination/)
is open until March 1, 2025. At one million euros, the prize is more
valuable than the Nobel Prize for Medicine, making it one of the most
highly endowed awards for medical research worldwide.


The international Broermann Medical Innovation Award recognizes research
results that demonstrate a high level of innovation for clinical
application and thus have the potential to improve the lives and health
of millions of people worldwide. The prize is aimed at scientists whose
research has been pioneering in the fields of medicine, biotechnology,
or related sciences.


The Broermann Medical Innovation Award was established in 2024 to honor
the vision and commitment of Dr. Bernard große Broermann, the founder of
the Asklepios Kliniken. The Broermann gemeinnützige GmbH sponsors the
award, and the University Hospital Giessen and Marburg (UKGM) manages
the organization. “With this award, we want to honor groundbreaking
medical discoveries and highlight those whose research brings real
improvements in the prevention or treatment of diseases,” says Prof.
Werner Seeger, Chairman of the Award Committee. For the Medical Director
of the UKGM, Prof. Friedrich Grimminger, the unique prize reflects the
clear conviction of the company founder: “Scientific excellence in
medicine is always an international team effort, but without the genius
of individual researchers, networks are limited in their impact. These
key players and drivers of medical innovation should be promoted and
recognized worldwide.”


Nomination process and deadlines


Nominations for the Broermann Medical Innovation Award can be submitted
until March 1, 2025. The incumbent Hessian Minister President will
present the award in December 2025 at the Hessian State Chancellery in
Wiesbaden.


Further information on the award, the nomination criteria, and the
selection process can be found at www.broermann-award.org.

For further information, please contact

Broermann Medical Innovation Award

Mirjam Malko

Tel.: +49 (0) 641 / 985-42310

E-Mail: [email protected]

Asklepios Kliniken

Corporate Communications and Marketing

Tel.: + 49 (0) 40 / 18 18-82 66 36

E-Mail: [email protected]

24-hour on-call service for the press office: +49 (0) 40 / 1818-82 8888

Visit Asklepios on the Internet, Facebook or YouTube:

www.asklepios.com

www.asklepios.com/konzern/gesundheitsmagazin

www.facebook.com/asklepioskliniken

www.youtube.com/asklepioskliniken

Rhön Klinikum AG


Corporate Communications and Marketing

Heike Ochmann

Press Spokeswoman

Tel.: +49 (0) 9771 / 65-12130

E-Mail: [email protected]

MEDICLIN AG

Dr. Janina Lossen
Press Spokeswoman

Tel:. +49 (0) 781 / 488-180
E-Mail: [email protected]

UKGM
Frank Steibli
Head of Communications and Press Spokesman

Tel.: +49 (0) 641 / 985-51020
Mobile: +49 (0) 160 / 7120456
E-Mail: [email protected]




Distributed by https://pressat.co.uk/


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.